These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
164 related articles for article (PubMed ID: 6523302)
41. Hyperthermic perfusion with chemotherapy for melanoma of the extremities. Ghussen F; Krüger I; Smalley RV; Groth W World J Surg; 1989; 13(5):598-602. PubMed ID: 2815804 [TBL] [Abstract][Full Text] [Related]
42. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis. Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758 [TBL] [Abstract][Full Text] [Related]
43. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS; J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537 [TBL] [Abstract][Full Text] [Related]
44. Palliation of regional symptoms of advanced extremity melanoma by isolated limb perfusion. Coit DG Cancer J Sci Am; 1995; 1(2):104-5. PubMed ID: 9166460 [No Abstract] [Full Text] [Related]
45. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan. Vaglini M; Santinami M; Manzi R; Inglese MG; Santoro N; Persiani L; Belli F Melanoma Res; 1994 Mar; 4 Suppl 1():35-8. PubMed ID: 8038594 [TBL] [Abstract][Full Text] [Related]
46. [Combined treatment of malignant tumors of the extremities. Regional perfusion chemotherapy]. Kolessov VI; Levin AO Minerva Med; 1970 Sep; 61(71):3673-5. PubMed ID: 4989391 [No Abstract] [Full Text] [Related]
47. [Isolated limb perfusion with tumor necrosis factor for malignancies of the limbs]. Abu-Abid S; Gutman M; Lev D; Inbar M; Chaitchik S; Sorkine P; Rudick V; Meller I; Klausner JM Harefuah; 1996 Oct; 131(7-8):227-32, 296, 295. PubMed ID: 8940515 [TBL] [Abstract][Full Text] [Related]
48. Microdialysis and response during regional chemotherapy by isolated limb infusion of melphalan for limb malignancies. Thompson JF; Siebert GA; Anissimov YG; Smithers BM; Doubrovsky A; Anderson CD; Roberts MS Br J Cancer; 2001 Jul; 85(2):157-65. PubMed ID: 11461070 [TBL] [Abstract][Full Text] [Related]
49. [Regional perfusion therapy of malignant tumors of the extremities]. Boeckl O; Hell E; Zimmermann G Dtsch Med Wochenschr; 1970 Mar; 95(13):707-10. PubMed ID: 4985407 [No Abstract] [Full Text] [Related]
50. The role of perfusion therapy in malignant melanoma. Key JA Can Med Assoc J; 1968 Jul; 99(1):11-6. PubMed ID: 5662998 [No Abstract] [Full Text] [Related]
51. Isolated limb perfusion for melanoma patients--a review of its indications and the role of tumour necrosis factor-alpha. Grünhagen DJ; de Wilt JH; van Geel AN; Eggermont AM Eur J Surg Oncol; 2006 May; 32(4):371-80. PubMed ID: 16520016 [TBL] [Abstract][Full Text] [Related]
52. Tumor necrosis factor-based isolated limb perfusion for soft tissue sarcoma and melanoma: ten years of successful antivascular therapy. Eggermont AM; ten Hagen TL Curr Oncol Rep; 2003 Mar; 5(2):79-80. PubMed ID: 12583823 [No Abstract] [Full Text] [Related]
53. Regional chemotherapy by isolation-perfusion: a ten year follow-up. McBride CM Panminerva Med; 1976; 18(1-2):11-3. PubMed ID: 1246444 [No Abstract] [Full Text] [Related]
54. [Hyperthermic chemotherapeutic isolation perfusion in malignant melanoma. Presentation of a case]. Pettavel J; Hardmeier T; Hessler C Schweiz Med Wochenschr; 1970 Aug; 100(33):1425-8. PubMed ID: 5525035 [No Abstract] [Full Text] [Related]
55. [Value of isolation-perfusion of the limbs in melanomas and sarcomas]. Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Kroon B Ann Chir; 1995; 49(1):9-12. PubMed ID: 7741477 [No Abstract] [Full Text] [Related]
56. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. Thompson JF; Lai DT; Ingvar C; Kam PC Melanoma Res; 1994 Mar; 4 Suppl 1():45-50. PubMed ID: 8038596 [TBL] [Abstract][Full Text] [Related]
57. [Leakage measurements with the dye extraction method and direct methotrexate level determination (enzyme immunoassay) during and after regional cytostatic limb perfusion]. Krauss J; Krause G; Hellthaler G Z Exp Chir Transplant Kunstliche Organe; 1989; 22(4):260-3. PubMed ID: 2675480 [TBL] [Abstract][Full Text] [Related]
59. History of regional chemotherapy for cancer of the extremities. Ariyan CE; Brady MS Int J Hyperthermia; 2008 May; 24(3):185-92. PubMed ID: 18392997 [TBL] [Abstract][Full Text] [Related]
60. Hyperthermic isolation limb perfusion for malignant melanoma: a review. Coit DG Cancer Invest; 1992; 10(4):277-84. PubMed ID: 1628227 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]